Montelukast as Add-On Therapy to Inhaled Corticosteroids in the Management of Asthma (The SAS Trial)

J Mark FitzGerald; Sylvain Foucart; Stephen Coyle; John Sampalis; Denis Haine; Eliofotisti Psaradellis; R Andrew McIvor

doi:10.1155/2009/593753

Canadian Respiratory Journal (Jan 2009)

Montelukast as Add-On Therapy to Inhaled Corticosteroids in the Management of Asthma (The SAS Trial)

J Mark FitzGerald,
Sylvain Foucart,
Stephen Coyle,
John Sampalis,
Denis Haine,
Eliofotisti Psaradellis,
R Andrew McIvor

Affiliations

J Mark FitzGerald: Respiratory Division, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Sylvain Foucart: Merck Frosst Canada Limited, Kirkland, Québec, Canada
Stephen Coyle: Medical Director, Four Rivers Clinics, Winnipeg, Manitoba, Canada
John Sampalis: Faculty of Medicine, McGill University, Canada
Denis Haine: JSS Medical Research Inc., Montreal, Quebec, Canada
Eliofotisti Psaradellis: JSS Medical Research Inc., Montreal, Quebec, Canada
R Andrew McIvor: Firestone Institute of Respiratory Health, McMaster University, Hamilton, Ontario, Canada

DOI: https://doi.org/10.1155/2009/593753
Journal volume & issue: Vol. 16, no. Suppl A
pp. 5A – 10A

Abstract

Read online

AIM: To evaluate the effectiveness of montelukast as add-on therapy for asthmatic patients who remain uncontrolled with low, moderate or high doses of inhaled corticosteroid monotherapy.

Published in Canadian Respiratory Journal

ISSN: 1198-2241 (Print); 1916-7245 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: https://onlinelibrary.wiley.com/journal/7503

About the journal